Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...

MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new ...

Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a Phase 3 clinical study ...

Results of a meta-analysis showed that all biologic agents were superior to placebo for improving short-term outcomes in moderate to severe plaque psoriasis.

In the VALOR trial, brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared ...

New long-term data of the investigational therapy icotrokinra show that it is able to achieve site-specific clear or almost clear skin in patients with plaque psoriasis, according to results of the ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Since revealing her plaque psoriasis diagnosis in 2015, La La Anthony has become a powerful voice for those living with the chronic skin condition. Plaque psoriasis—often mistaken for dry skin or ...

Over 8 million adults in the U.S. experience plaque psoriasis — a chronic autoimmune disease that causes painful, raised, scaly spots on the skin. People with plaque psoriasis often employ a host of ...

MARIETTA, Ga. - Greg Morrison of Marietta has been living with plaque psoriasis for more than 30 years. "The rash, it itches constantly," Morrison says. "It flakes. It kind of pinches you, and then ...